BTIG Rates SOPHiA GENETICS (SOPH) buy, $8 Price Target

BTIG analyst Mark Massaro maintains confidence in SOPHiA GENETICS with an $8 price target, a 52.67% upside from the current price.

By EarningsIQ Research Desk · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 18, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated SOPHiA GENETICS SA ($SOPH) "buy" with a $8 price target on June 15, 2026.

Since the rating, $SOPH is up 6.6% after 1 week, up 15.2% after 1 month and up 34.3% to date (from the $5.01 close on Jun 15, 2026).

SOPH SOPHiA GENETICS SA

$6.73 +44.11% year to date

Daily close · Oct 16, 2026

Key Points

BTIG analyst Mark Massaro reiterated a buy rating for SOPHiA GENETICS on June 15, 2026, with a price target of $8.
BTIG's $8 price target implies 52.67% upside from SOPHiA GENETICS SA's ($SOPH) current $5.24 share price.
SOPHiA GENETICS, trading at $4.88, has a market cap of about $359.7 million and operates in the healthcare sector.
Royce & Associates LP significantly increased their holdings in the company, raising their shares by 1,386,055 to a total of 1,816,312.

Get $SOPH trade alerts by text

We text you when insiders, Congress or big funds trade $SOPH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SOPHiA GENETICS SA alert may contain errors. Disclosures

BTIG analyst Mark Massaro reiterated his buy rating for SOPHiA GENETICS SA (NasdaqGS: SOPH) on June 15, 2026. He maintained his price target at $8, signaling continued confidence in the company's growth prospects. SOPHiA GENETICS shares were trading around $4.88 following this announcement.

Other Institutional Activity in SOPHiA GENETICS

Royce & Associates LP made a notable move by adding 1,386,055 shares, bringing their total to 1,816,312 shares valued at approximately $8.99 million. Meanwhile, Soleus Capital Management, L.P. increased their position by 1,850,000 shares, now holding 1,850,000 shares worth about $9.16 million. Generation Investment Management LLP and Akre Capital Management LLC maintained their positions with 6,789,560 shares and 3,719,140 shares, respectively.

SOPHiA GENETICS SA Stock Down 28.1%

Shares of SOPHiA GENETICS (NasdaqGS: SOPH) traded near $4.88. The company has a market cap of approximately $359.7 million. While it isn't currently profitable, with no meaningful P/E ratio, it has a forward P/E of -8.95. The stock's 52-week range is between $2.59 and $5.70, with a beta of 0.985. The 50-day moving average stands at $4.99, while the 200-day moving average is $4.64.

12-month forecast

$SOPH price target

SOPHiA GENETICS SA daily closes and this analyst's $8 target. Not advice.

Recent Earnings

SOPHiA GENETICS reported revenue of $81.18 million, reflecting a growth rate of 22%. However, the company posted a net margin of -99.7% and a return on equity of -123.3%. The next earnings report is anticipated on August 4, 2026.

Insider Buying and Selling at SOPHiA GENETICS SA

Recent insider transactions include Chief Financial Officer George Cardoza purchasing 20,000 shares at $4.95 each on June 5, 2026. Meanwhile, Chief Executive Officer Jurgi Camblong sold 8,500 shares at $5.24 on June 10, 2026, under a planned sale.

Analysts Set New Price Targets

On June 15, 2026, BTIG reiterated its buy rating for SOPHiA GENETICS, maintaining a price target of $8. The consensus among analysts is a buy rating with a mean target price of $8, supported by three analyst opinions.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company based in Rolle, Switzerland. It provides a cloud-native software platform called SOPHiA DDM, which helps analyze and interpret complex data sets in the medical field. The company works with hospitals, labs, and biopharmaceutical firms worldwide. Dr. Jurgi Camblong leads the company as CEO.

Bottom Line

BTIG's reiteration of a buy rating for SOPHiA GENETICS reflects ongoing confidence in the company's potential. Investors often track such ratings for insights into stock performance. However, it's important to remember that analyst ratings are based on past data and projections, and actual results may differ.